You are here: Industry Insights > PFS

News List

Novartis Consistently improved PFS in Patients with PIK3CA Mutated HR+/HER2- Advanced Breast Cancer americanpharmaceuticalreview
December 10, 2018
Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with.....
Roche's first-line Tecentriq combo scores accelerated FDA review pharmafile
December 07, 2018
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of extensive-stage small cell lung cancer (ESCLC).
Imbruvica Plus Obinutuzumab Shown to Increase Survival for Leukemia/Lymphoma americanpharmaceuticalreview
December 05, 2018
Janssen Pharmaceutical announced results from the Phase 3 iLLUMINATE (PCYC-1130) study, which showed the combination of Imbruvica (ibrutinib) plus obinutuzumab......
EU OKs first-line use of Ipsen’s Cabometyx pharmatimes
July 12, 2018
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Data show Imnovid-based triple therapy PFS benefit in blood cancer pharmatimes
July 06, 2018
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.

Previous page 1 2 Next page